Page 597 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

CHAPTER 28 ■ Disorders of Hemostasis and Thrombosis: Blood Coagulation Factors, Hypercoagulable State, and Anticoagulant Therapy 581

REVIEW QUESTIONS (continued)

*8. Te ha ark o secon ary brino ysis is the resence o 15. Pregnancy can cause a

A. brin s it ro ucts A. ri ary hy ercoagu ab e state

B. brin egra ation ro ucts B. secon ary hy ercoagu ab e state

C. brin ono ers

D. a o the above *16. A characteristic o circu ating anticoagu ants is which
o the o owing?

9. DIC is characterize by A. T e ost co on s eci c actor inhibitor

A. icrovascu ar thro bosis B. Acquire inhibitors o c otting roteins

B. brin e osition C. A so known as anti hos ho i i or anticar io i in

C. active brino ysis D. None o the above

D. a o the above *17. A characteristic o u us anticoagu ant is which o the

o owing?
Te Hypercoagulable State A. T e ost co on s eci c actor inhibitor

*10. Which o the o owing actors can contribute to B. Acquire inhibitors o c otting roteins

hy ercoagu ation? C. A so known as anti hos ho i i or anticar io i in
A. Vascu ar en othe ia a age D. None o the above

B. Increase b oo f ow
C. Decrease ate ets *18. A characteristic o actor VIII inhibitor is which o the

D. Decrease titers o c otting actors o owing?
A. T e ost co on s eci c actor inhibitor
*11. Antithro bin e ciency can cause a B. Acquire inhibitors o c otting roteins

A. ri ary hy ercoagu ab e state C. A so known as anti hos ho i i or anticar io i in
B. secon ary hy ercoagu ab e state D. None o the above

*12. Ora contrace tives can cause a Anticoagulant T erapy
A. ri ary hy ercoagu ab e state

B. secon ary hy ercoagu ab e state 19. War arin is a vita in antagonist.
A. B
*13. Protein C e ciency can cause a B. C

A. ri ary hy ercoagu ab e state C. D
B. secon ary hy ercoagu ab e state D. K

14. Cancer can cause a
A. ri ary hy ercoagu ab e state

B. secon ary hy ercoagu ab e state

Caste one D. A case stu y in coagu ation, Adv Lab, 15(1):51–53, 2006.
COMPANION RES OURCES Chaturve i S, McCrae KR. T e anti hos ho i i syn ro e: sti an

enig a, Hematology Am Soc Hematol Educ Program, 2015:53–60,
htt ://the oint. ww.co / urgeon6e
2015.

Each stu ent is encourage to access an use the Web- Cuker A, Siega D. Monitoring an reversa o irect ora anticoagu-

base co anion resources eve o e or this cha ter. ants, Hematology Am Soc Hematol Educ Program, 2015:117–124,

Here you wi n a itiona earning too s to increase 2015.

your un erstan ing o the conce ts an c inica a ica- Danese S, et a . T e rotein C athway in tissue inf a ation an
injury: athogenic ro e an thera eutic i ications, Blood,
tions o the cha ter.
115(6):1121–1130, 2010.

Fe erici AB. VWF ro e ti e: a use u arker in VWD, Blood,

108(10):3229, 2006.

BIBLIOGRAPHY Ferro A. Newer anti ate et agents in acute coronary syn ro e, BMJ,

352:h7025, 2016.

Bates SM, Ginsberg JS. reat ent o ee -vein thro bosis, N Engl Frits a GA, Marques MB. o 10 rob e s in coagu ation, Adv Med

Med, 351(3):268–277, 2004. Lab Pro , 16(13):22–29, 2004.
Bernar GR, et a . E cacy an sa ety o reco binant hu an activate Frits a MG. Use o b oo ro ucts an actor concentrates or coagu-

rotein C or severe se sis, N Engl J Med, 344(10):699–709, 2001. ation thera y, Clin Lab Sci, 16(2):115–119, 2003.